Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/11600
Full metadata record
DC FieldValueLanguage
dc.contributor.authorEbert, Lisa Men
dc.contributor.authorMacRaild, Sarah Een
dc.contributor.authorZanker, Damienen
dc.contributor.authorDavis, Ian Den
dc.contributor.authorCebon, Jonathan Sen
dc.contributor.authorChen, Weisanen
dc.date.accessioned2015-05-16T01:12:58Z
dc.date.available2015-05-16T01:12:58Z
dc.date.issued2012-10-26en
dc.identifier.citationPLoS One 2012; 7(10): e48424en
dc.identifier.govdoc23110239en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/11600en
dc.description.abstractCancer vaccines are designed to expand tumor antigen-specific T cells with effector function. However, they may also inadvertently expand regulatory T cells (Treg), which could seriously hamper clinical efficacy. To address this possibility, we developed a novel assay to detect antigen-specific Treg based on down-regulation of surface CD3 following TCR engagement, and used this approach to screen for Treg specific to the NY-ESO-1 tumor antigen in melanoma patients treated with the NY-ESO-1/ISCOMATRIX™ cancer vaccine. All patients tested had Treg (CD25(bright) FoxP3(+) CD127(neg)) specific for at least one NY-ESO-1 epitope in the blood. Strikingly, comparison with pre-treatment samples revealed that many of these responses were induced or boosted by vaccination. The most frequently detected response was toward the HLA-DP4-restricted NY-ESO-1(157-170) epitope, which is also recognized by effector T cells. Notably, functional Treg specific for an HLA-DR-restricted epitope within the NY-ESO-1(115-132) peptide were also identified at high frequency in tumor tissue, suggesting that NY-ESO-1-specific Treg may suppress local anti-tumor immune responses. Together, our data provide compelling evidence for the ability of a cancer vaccine to expand tumor antigen-specific Treg in the setting of advanced cancer, a finding which should be given serious consideration in the design of future cancer vaccine clinical trials.en
dc.language.isoenen
dc.subject.otherCancer Vaccines.therapeutic useen
dc.subject.otherCells, Cultureden
dc.subject.otherEpitopes.immunologyen
dc.subject.otherFlow Cytometryen
dc.subject.otherHumansen
dc.subject.otherLeukocytes, Mononuclear.metabolismen
dc.subject.otherMelanoma.immunology.pathology.therapyen
dc.subject.otherT-Lymphocytes, Regulatory.immunologyen
dc.titleA cancer vaccine induces expansion of NY-ESO-1-specific regulatory T cells in patients with advanced melanoma.en
dc.typeJournal Articleen
dc.identifier.journaltitlePLoS Oneen
dc.identifier.affiliationLudwig Institute for Cancer Research (Melbourne-Austin Branch), Melbourne, Australiaen
dc.identifier.doi10.1371/journal.pone.0048424en
dc.description.pagese48424en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/23110239en
dc.type.austinJournal Articleen
local.name.researcherCebon, Jonathan S
item.languageiso639-1en-
item.openairetypeJournal Article-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.cerifentitytypePublications-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

18
checked on Nov 7, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.